Douglas Cowan

Has grant

Staff Scientist

Boston Children's Hospital
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Recent Grants

Grant: Close

Characterization of Cardiac Progenitor Cells from Adult Skeletal Muscle

Open Date: 2012-07-01

Close Date: 2015-06-30

Grant: Close

Expansion and Directed Differentiation of Adult Side Population Stem Cells

Open Date: 2007-07-18

Close Date: 2013-06-30

Grant: Close

Cardiac Conduction through Engineered Tissue

Open Date: 2002-01-18

Close Date: 2011-05-31

Articles (11)

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2025

Year:

2024

Year:

2024

Diabetes mellitus can cause impaired and delayed wound healing, leading to lower extremity amputations; however, the mechanisms underlying the regulation of vascular endothelial growth factor (VEGF)-dependent angiogenesis remain uncertain and could reveal new therapeutic targets. In our study, the molecular underpinnings of endothelial dysfunction in diabetes were investigated, focusing on the roles of Disabled-2 (Dab2) and Forkhead Box M1 (FoxM1) in VEGF receptor 2 (VEGFR2) signaling and endothelial cell (EC) function. Bulk RNA-sequencing analysis identified significant downregulation of Dab2 in high concentrations glucose treated primary mouse skin ECs, simulating hyperglycemic conditions in diabetes mellitus. In diabetic mice with a genetic EC deficiency of Dab2 angiogenesis was reduced in vivo and in vitro when compared with wild-type mice. Restoration of Dab2 expression by injected mRNA-containing lipid nanoparticles rescued impaired angiogenesis and wound healing in diabetic mice. At the same time, FoxM1 was downregulated in skin ECs subjected to high glucose conditions as determined by RNA-sequencing analysis. FoxM1 was found to bind to the Dab2 promoter, regulating its expression and influencing VEGFR2 signaling. The FoxM1 inhibitor FDI-6 reduced Dab2 expression and phosphorylation of VEGFR2. These findings indicate that restoring Dab2 expression through targeted therapies can enhance angiogenesis and wound repair in diabetes. To explore this therapeutic potential, we tested LyP-1-conjugated lipid nanoparticles (LNPs) containing Dab2 or control mRNAs to target ECs and found the former significantly improved wound healing and angiogenesis in diabetic mice. This study provides evidence of the crucial roles of Dab2 and FoxM1 in diabetic endothelial dysfunction and establishes targeted delivery as a promising treatment for diabetic vascular complications.

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Collaborators (3)

Yao Wei Lu

Assistant Professor

University of Southern California

UNITED STATES
View details

Hong Chen

Professor of Surgery

Boston Children's Hospital/Harvard Medical School

UNITED STATES
View details

Kui Cui

Assistant Professor

Baylor College of Medicine

UNITED STATES
View details